Cyclopropylamine LSD1 Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with lysine-specific demethylase-1 (LSD1) activity, such as cancer, lack effective inhibitors that can selectively target and modulate LSD1, leading to inadequate therapeutic outcomes due to LSD1's role in epigenetic regulation and resistance in cancer cells.
Innovation Solution
Development of specific compounds, such as those represented by Formula I, which act as LSD1 inhibitors, capable of selectively inhibiting LSD1 activity, thereby modulating its function and potentially treating LSD1-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for LSD1-associated diseases, then therapeutic outcomes are inadequate, but no effective selective inhibitors are available
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (cyclopropylamine core structure, particular substituent patterns) that interact selectively with LSD1's unique active site architecture. The compounds are engineered to fit LSD1's catalytic domain with high specificity, distinguishing it from other demethylases through localized structural adaptations in the inhibitor molecules.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules (substituent types, positions, and configurations on the cyclopropylamine core) to optimize binding affinity and selectivity for LSD1. This includes adjusting electronic, steric, and hydrophobic parameters to achieve selective inhibition of LSD1 while sparing other enzymes.
2Productivity
If LSD1 activity is not inhibited, then cancer cells maintain resistance and abnormal proliferation, but existing treatments cannot effectively target LSD1
Solution Approach 1:
The patent applies preliminary action by conducting extensive structure-activity relationship (SAR) studies and computational modeling before finalizing the inhibitor structures. The cyclopropylamine core and substituent patterns were optimized in advance through preliminary screening and design, ensuring that the final compounds possess both the desired biological activity against LSD1 and suitable pharmacological properties for development.
3Reliability
If selective LSD1 inhibitors are developed, then therapeutic efficacy improves, but compound design and optimization becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a cyclopropylamine core structure that provides the essential binding scaffold, and variable substituent groups (Ar1, Ar2, R1-R6) that can be independently optimized for specificity and affinity. This modular approach allows systematic optimization of each segment's contribution to LSD1 binding while maintaining overall molecular manageability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit LSD1, normalizing altered gene expressions, reducing cancer cell proliferation, and promoting apoptosis, offering a potential therapeutic benefit for LSD1-associated diseases, including various cancers and viral infections.
Implementation Method 1
The compounds effectively inhibit LSD1, normalizing altered gene expressions
Data Source
AI summary
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.